As of June 17, 2025, Hansa Biopharma AB (HNSA.ST) reports a Current Ratio of 2.29.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Hansa Biopharma AB's Current Ratio
Over recent years, Hansa Biopharma AB's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2024-12-31 | 2.29 |
| 2023-12-31 | 2.66 |
| 2022-12-31 | 6.06 |
| 2021-12-31 | 5.50 |
| 2020-12-31 | 12.20 |
This slight downward trend highlights how Hansa Biopharma AB manages its short-term assets and liabilities over time.
Comparing Hansa Biopharma AB's Current Ratio to Peers
To better understand Hansa Biopharma AB's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Hansa Biopharma AB (HNSA.ST) | 2.29 |
| Molecular Partners AG (MOLN.SW) | 14.31 |
| Synairgen PLC (SNG.L) | 9.01 |
| Tiziana Life Sciences PLC (TILS.L) | 8.79 |
| Biogaia AB (BIOG B.ST) | 7.81 |
| Bioventix PLC (BVXP.L) | 7.42 |
Compared to its competitors, Hansa Biopharma AB's Current Ratio is about average compared to peers, reflecting balanced short-term asset management.